Nektar Therapeutics and Jonathan Zalevsky, PhD, are exploring REZPEG's potential in treating alopecia, atopic dermatitis, lupus, and diabetes, aiming for groundbreaking autoimmune therapies.
Jonathan Zalevsky, PhD
Advertisement
Articles by Jonathan Zalevsky, PhD
Nektar Therapeutics explores rezpegaldesleukin's potential as a groundbreaking treatment for alopecia areata, aiming for FDA approval and improved patient outcomes.
Jonathan Zalevsky, PhD, discusses the unmet needs in atopic dermatitis treatment, the potential of Rezpeg, and the importance of novel therapies.
Jonathan Zalevsky, PhD, discusses the fundamentally different path of Rezpeg compared with existing IL-4 and IL-13 inhibitors in atopic dermatitis.
Zalevsky shares insights into the implications of the designation and what it may mean for Rezpeg's development timeline.
Advertisement
Latest Updated Articles
Tackling Unmet Needs in Dermatology With RezpegaldesleukinPublished: February 18th 2025 | Updated:
Jonathan Zalevsky, PhD, on Rezpegaldesleukin’s Biologic Approach to Alopecia AreataPublished: August 8th 2025 | Updated:
- Rezpeg vs Existing Therapies: A Paradigm Shift in Atopic Dermatitis Treatment
Published: February 17th 2025 | Updated:
- Nektar's Jonathan Zalevsky, PhD, Dives Into Rezpegaldesleukin Fast Track Designation for Atopic Dermatitis
Published: February 14th 2025 | Updated:
How Nektar's Rezpegaldesleukin Could Redefine Treatment for Autoimmune DisordersPublished: August 11th 2025 | Updated:
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Reviewing Type 2 Inflammation Through a Different Lens
3
Derm Dispatch: What 'Free to Be Me' Means to Tori Spelling and Stella McDermott
4
Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic
5
